Pasithea Therapeutics Corp.
KTTA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $15 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $5 | $17 |
| Gross Profit | $0 | $0 | -$5 | -$2 |
| % Margin | – | – | – | -14.7% |
| R&D Expenses | $7,198 | $8,101 | $2,665 | $0 |
| G&A Expenses | $7,051 | $0 | $0 | $0 |
| SG&A Expenses | $7,051 | $0 | $9,918 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $7,879 | $0 | $4,505 |
| Operating Expenses | $14,250 | $15,979 | $12,584 | $4,505 |
| Operating Income | -$14,250 | -$15,979 | -$12,589 | -$4,507 |
| % Margin | – | – | – | -29,925.7% |
| Other Income/Exp. Net | $345 | $472 | $861 | $2,334 |
| Pre-Tax Income | -$13,905 | -$15,508 | -$11,728 | -$2,174 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$13,905 | -$15,962 | -$13,936 | -$2,174 |
| % Margin | – | – | – | -14,430.5% |
| EPS | -12.69 | -12.65 | -10.34 | -1.89 |
| % Growth | -0.3% | -22.3% | -447.1% | – |
| EPS Diluted | -12.69 | -13.01 | -10.34 | -1.89 |
| Weighted Avg Shares Out | 1,096 | 1,262 | 1,262 | 1,150 |
| Weighted Avg Shares Out Dil | 1,096 | 1,227 | 1,262 | 1,150 |
| Supplemental Information | – | – | – | – |
| Interest Income | $423 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $1 |
| Depreciation & Amortization | $649 | $648 | $5 | $1 |
| EBITDA | -$13,601 | -$15,331 | -$11,723 | -$4,506 |
| % Margin | – | – | – | -29,916.6% |